The history of the development of buprenorphine as an addiction therapeutic

@article{Campbell2012TheHO,
  title={The history of the development of buprenorphine as an addiction therapeutic},
  author={Nancy Campbell and Anne M Lovell},
  journal={Annals of the New York Academy of Sciences},
  year={2012},
  volume={1248}
}
This paper traces the early 21st century success of the agonist–antagonist buprenorphine and the combination drug buprenorphine with naloxone within the broader quest to develop addiction therapeutics that began in the 1920s as the search for a nonaddictive analgesic. Drawing on archival research, document analysis, and interviews with contemporary actors, this paper situates the social organization of laboratory‐based and clinical research within the domestic and international confluence of… Expand
Polluting pharmaceutical atmospheres: Compulsion, resistance, and symbolism of buprenorphine in Norway
TLDR
It is shown that the social history of the medication is as significant as its pharmacological qualities for various treatment effects and the reciprocal shaping of lived experiences and institutional forces surrounding pharmaceutical use in general and opioids in particular. Expand
Promise and Deceit: Pharmakos, Drug Replacement Therapy, and the Perils of Experience
  • Todd Meyers
  • Psychology, Medicine
  • Culture, medicine and psychiatry
  • 2014
TLDR
The paper demonstrates how the patient-subject comes to represent therapeutic promise by allowing for the possibility of (and often performing) deceit, in the context of opioid replacement therapy. Expand
Medicalization and Biomedicalization: Does the Diseasing of Addiction Fit the Frame?
Purpose – The chapter examines the historical pattern of interconnections between drug policy, research, and treatment in light of recent theoretical developments in the medicalization thesisExpand
Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan
TLDR
This is the first grounded work in Asia that empirically examines and theoretically explains the diversion of B/N from an assemblage perspective and suggests establishing new associations by incorporating addiction treatment into NHI. Expand
Influence of buprenorphine replacement therapy
TLDR
It appears that there is less potential for drug abuse when buprenorphine is used instead of methadone, and social reintegration is an important aspect of social rehabilitation of opioid addicts, and it is therefore extremely important to recognize psychological and social factors that can act as protective factors, but also as risk factors. Expand
A Comparison of Suboxone and Methadone in the Treatment of Opiate Addiction
TLDR
Suboxone and methadone are both proven to be effective treatment options for opiate addiction, and the research does not indicate that one medication is a better option than the other. Expand
To Be Free and Normal: Addiction, Governance, and the Therapeutics of Buprenorphine.
TLDR
It is argued that the therapeutics of buprenorphine govern patients and providers through this desire for freedom and normalcy, and is thus a technology of governmentality that extends neoliberal discourses and values and produces self-governing subjects. Expand
New developments in managing opioid addiction: impact of a subdermal buprenorphine implant
TLDR
The opioid abuse epidemic is introduced, existing medications used for therapy are examined, and Probuphine is highlighted as a new treatment option. Expand
Buprenorphine for opioid use disorder: The role of public funding in its development.
TLDR
The public sector's contribution to the development of buprenorphine for OUD is estimated at an estimated $62.3 million, which limits access to this important treatment. Expand
Opiate Substitution Treatment: Poisoned Bodies and the History of Substitution
TLDR
The genealogical method is used to map out the historical conditions from which it became rational and necessary for medical experts to govern the heroin-dependent body through the practice of substitute prescribing during the latter half of the 19th Century. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 118 REFERENCES
A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts
TLDR
The results of this clinical trial indicated that buprenorphine was acceptable to patients and as effective as methadone in the detoxification treatment of heroin addicts. Expand
OPIATE WITHDRAWAL SYNDROME: ACUTE AND PROTRACTED ASPECTS
  • D. Jasinski
  • Medicine
  • Annals of the New York Academy of Sciences
  • 1981
TLDR
This presentation will summarize the highlight evolving concepts of the abstinence syndrome developed at the ARC and indicates the means for developing analgesics of lower abuse potential than morphine. Expand
From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
TLDR
The development of buprenorphine, a partial opioid agonist, as an effective treatment for opioid addiction reopened the possibility for having a less burdensome oversight process, especially because of its reduced toxicity if ingested by non-tolerant individuals. Expand
The history of a public science: How the Addiction Research Center became the NIDA Intramural Research Program.
  • N. Campbell
  • Psychology, Medicine
  • Drug and alcohol dependence
  • 2010
The Addiction Research Center in Lexngton, Kentucky, accomplished many of he formative studies in the field of drug buse from its inception and into the 970s (Acker, 2002; Campbell, 2007). ThisExpand
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
TLDR
Buprenorphine has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics. Expand
A controlled trial of buprenorphine treatment for opioid dependence.
TLDR
Buprenorphine was as effective as methadone, 60 mg/d, and both were superior to methad one, 20 mg/D, in reducing illicit opioid use and maintaining patients in treatment for 25 weeks. Expand
Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
TLDR
The increases in diversion and abuse measures indicate the need to take active attempts to curb diversion and Abuse as well as continuous monitoring and surveillance of all buprenorphine products, although these increases parallel the increased number of tablets sold. Expand
A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.
TLDR
A group of 22 patients, previously addicted to diacetylmorphine (heroin), have been stabilized with oral methadone hydrochloride, and with this medication, patients have shown marked improvement; they have returned to school, obtained jobs, and have become reconciled with their families. Expand
Human pharmacology of narcotic antagonists.
  • D. Jasinski
  • Medicine
  • British journal of clinical pharmacology
  • 1979
1 Human studies at the Addiction Research Center enable narcotic antagonists to be classified into three subgroups: (1) nalorphine-like agents; (2) pure antagonists; and (3) morphine-like agents. 2Expand
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.
TLDR
It is demonstrated that a placebo controlled study with a behavioral choice component is an effective means of assessing the potential efficacy and acceptability of new pharmacotherapies for opioid dependence. Expand
...
1
2
3
4
5
...